Tebow 2-10-26 Notice of Intent to Sole Source.docx

Notice of Intent to Sole Source - DUNCAN E TEBOW

The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to Duncan E. Tebow, 9811 CAPITOL VIEW AVE, SILVER SPRING MD 20910-1031, in accordance with the authority under FAR Part 13.501(a). This procurement is being conducted under simplified acquisition procedures in accordance with FAR Parts 12 and 13, including subpart 13.5. The NAICS code is 238990 - All Other Specialty Trade Contractors.

The White Oak Animal Program (WOAP) is responsible for ensuring that the animal facility in Building 10 on the U.S. Federal Drug Administration’s (FDA) White Oak (WO) campus functions in conformance with applicable laws, policies and guidelines that govern the humane care and use of animals used in biomedical research. The facility is registered with the United States Department of Agriculture (USDA), has a current assurance on file with the National Institutes of Health’s (NIH) Office of Laboratory Animal Welfare, and is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

The Institutional Official (IO) of the WOC IACUC and the WOC AP is required by law to ensure a nonaffiliated member is appointed to its IACUC. The Center for Biologics Evaluation & Research (CBER) Director is the IO and appoints the nonaffiliated member. The nonaffiliated member is an individual who represents general community interests in the proper care and use of animals, is not a laboratory animal user, and is not affiliated, nor has an immediate family member who is affiliated with FDA, CBER, and the WOAP. The Guide for the Care and Use of Laboratory Animals is a reference utilized by AAALAC when it assesses animal facilities for accreditation. The guide advises that the non-affiliated member (referred to as contractor from this point forward) may receive a modest stipend for ancillary expenses, and the WOAP choses to adopt this practice.

This notice is not a request for competitive quotes. However, any party that believes it is capable of meeting the requirements as stated herein may submit a written response, i.e. capability statement, which clearly supports and demonstrates its ability to perform the requirements. Any response shall be received by the response date and time of this notice. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.

Response Date: 10:00 a.m. ET on February 20, 2026. Responses must be emailed to Bonnie M. Amond at bonnie.amond@fda.hhs.gov with a cc to James G. Whitt at james.whitt@fda.hhs.gov.